Kyowa Kirin Co., Ltd.
PharmaTokyo, Japan, Japan · Est. 1949 · 3,700 employees
Kyowa Kirin is a Japanese pharmaceutical company focused on developing and commercializing innovative medicines in oncology, immunology, nephrology, and other therapeutic areas.
16
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
11
Indications↗
Distinct diseases across all programs
155
Clinical Trials↗
All sponsored trials (all statuses)
2
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
16 drugs in development
Phase 31
Phase 21
Phase 114
By Therapeutic Area
top 4
Oncology
732%
Ophthalmology
15%
Cardiovascular
15%
Immunology
15%
R&D Momentum
41/100
Pipeline Velocity
0/100
Trial Completion Rate
89/100
Pipeline Concentration
40/100
Pipeline Freshness
75/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
- ↗Active in Ophthalmology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 2, 2026
Recruiting
A Phase 1, Placebo-Controlled, Double-Blind, Randomized, Single and Multiple Ascending-Dose Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension
Jul 2, 2026
Recruiting
A Phase I, Multicenter, Non-controlled, Open-label, Non-randomized, Dose-escalation Study of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.
Earlier
May 2, 2025TrialAssessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
Dec 1, 2024TrialEvaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）
Oct 9, 2024TrialA First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
Jan 31, 2024TrialStudy to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
Jan 18, 2024TrialA Study of KK2269 in Adult Participants With Solid Tumors
Jan 9, 2024TrialStudy to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
4 more events
Nov 1, 2023TrialA Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
Sep 7, 2022TrialStudy to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO
Aug 3, 2022TrialA Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus
Nov 1, 2021TrialStudy to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH
Details
Company Info
Company Overview
$9.5B
Mkt Cap
$2.2B
Revenue
—
Cash
CEOYoshihiko Hatanaka
Founded1949
Employees3,700
HQTokyo, Japan, Japan
Websitekyowakirin.com/
LinkedInCompany Page
Therapeutic Focus
oncologyimmunologynephrologyhematology
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(1 drug)
—
1
—
—
—
Cardiovascular(1 drug)
Immunology(1 drug)
—
1
—
—
—
Immunology(1 drug)
Oncology(7 drugs)
—
7
1
—
—
Oncology(7 drugs)
Ophthalmology(1 drug)
—
1
1
—
—
Ophthalmology(1 drug)
Unknown / Other(12 drugs)
—
10
1
1
—
Unknown / Other(12 drugs)
Regulatory
Regulatory Timeline
19971 event
FDAMay 29
Fareston — FARESTON
Application NDA020497 (NDA)
20182 events
FDAAug 8
POTELIGEO — POTELIGEO
Application BLA761051 (BLA)
FDAApr 17
CRYSVITA — CRYSVITA
Application BLA761068 (BLA)
20191 event
FDAAug 27
Nourianz — NOURIANZ
Application NDA022075 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)